paraphrase: Thanks for thanks mike.
compname reports q2 earnings per share $1.08.
q4 revenue $6.9 billion versus refinitiv ibes estimate of $6'.
q2 adjusted earnings per share $1.42.
q2 sales $4.7 billion versus refinitiv ibes estimate of $3.8 billion.
qtrly net sales were strong.
compname posts q1 earnings per share $0.68.
qtrly medicine sales increased 18 percent in hormirum business compared to prior year.
compname reports second quarter 2021 results.
q2 sales $1.7 billion versus refinitiv ibes estimate of $1 billion.
qtrly worldwide sales grew 9.1%.
q2 sales increased 2%.
qtrly global imbruvica revenues were $626 million, up 42% from refinitiv ibes estimate of $521.1 million for q3 of 2021.
compname reports q2 earnings per share $528 million.
qtrly global viekira sales totaled $225 million versus refinitiv ibes estimate of $266.7 million.
sees u.s. earnings per share growth in coming weeks.
